RNA Based Therapeutic Companies, Business & Management Outlook
The global RNA based therapeutic market was evaluated at US$ 6.83 billion in 2023 and is expected to attain around US$ 40.81 billion by 2034, growing at a CAGR of 17.64% from 2024 to 2034.
Top Companies in RNA Based Therapeutic Market are:
- ISIS Pharmaceuticals
- Quark Pharmaceuticals
- Alnylam Pharmaceuticals
- Dicerna Pharmaceuticals
- Tekmira Pharmaceuticals Corp.
- Benitec Biopharma Limited
- Genzyme Corporation
- Silence Therapeutics PLC
- Cenix BioScience GmbH
International Trade Data: Consignee and Shipper Details with HS Code Descriptions
| CONSIGNEE_NAME | SHIPPER_NAME | HS_CODE_DESCRIPTION | LOADING_PORT | SUMOFQUANTITY | SUMOFWEIGHT |
| SANDOZ INC | SANDOZ PRIVATE LIMITED | Medicaments consisting of mixed or unmixed products for therapeutic or prophylactic uses, in dosage forms | 53313, JAWAHARLAL NEHRU | 418236 | 24340 |
| EUCATEX OF NORTH AMERICA INC | EUCATEX INDUSTRIA E COMERCIO LTDA | Diagnostic or laboratory reagents on a backing, prepared diagnostic or laboratory reagents | 35177, SAO PAULO | 397700 | 4846000000 |
| RB HEALTH US LLC | RECKITT BENCKISER HEALTHCARE UK LIMITED | Medicaments consisting of mixed or unmixed products for therapeutic or prophylactic uses, in dosage forms | 41251, LIVERPOOL | 232401 | 335893 |
| TIME CAP LABS INC | MARKSANS PHARMA LIMITED | Medicaments consisting of mixed or unmixed products for therapeutic or prophylactic uses, in dosage forms | 53313, JAWAHARLAL NEHRU | 201133 | 845370 |
| ATRIUM MEDICAL CORP | HOLOPACK VERPACKUNGSTECHNIK GMBH | Medicaments consisting of mixed or unmixed products for therapeutic or prophylactic uses, in dosage forms | 42870, BREMERHAVEN | 129351 | 30971 |
| LIFESCAN GLOBAL CORP | LIFESCAN SCOTLAND LIMITED | Diagnostic or laboratory reagents on a backing, excluding those of heading 3006 | 41352, CORYTON | 114553 | 111606 |
| AUROLOGISTICS LLC | AUROBINDO PHARMA LIMITED | Medicaments containing penicillins or derivatives thereof, with a penicillanic acid structure | 53313, JAWAHARLAL NEHRU | 72927 | 261709 |
| KUEHNE AND NAGEL S A | KUEHNE AND NAGEL N V S A ANTWERPEN | Medicaments consisting of mixed or unmixed products for therapeutic or prophylactic uses, in dosage forms | 42305, ANVERS | 50058 | 6251 |
| SUMITOMO PHARMA AMERICA INC | PIRAMAL PHARMA LIMITED | Medicaments consisting of mixed or unmixed products for therapeutic or prophylactic uses, in dosage forms | 53313, JAWAHARLAL NEHRU | 39833 | 53745 |
| NEW WORLD IMPORT INC | GALENTIC PHARMA INDIA PRIVATE LIMITED | Medicaments consisting of mixed or unmixed products for therapeutic or prophylactic uses, in dosage forms | 53306, MUNDRA | 39210 | 91127 |
Recent Developments in the RNA Based Therapeutic Market
- In October 2024, Urban Therapeutics Inc. announced a vision to pioneer the future of RNA interference (RNAi)-based medicine. Urban Therapeutics aims to foster the next generation of small interfering RNA (siRNA) RNAi-based “triggers” to create powerful and sustainable products and expand the broad therapeutic spectrum of RNAi-based medicines.
- In February 2024, UT Southwestern Medical Center partnered with Pfizer to develop RNA-enhanced delivery technology for gene therapy through Dallas Medical Center’s Genetic Medicine Engineering Program.
- In November 2024, Maravai LifeSciences, Inc., a global provider of life science reagents and services to scientists and biotechnology innovators, announced its agreement to acquire Officinae Bio's DNA and RNA business. The acquisition will expand Maravai and TriLink BioTechnologies’ ability to help customers develop novel nucleic acid therapies.
If you have any questions, please feel free to contact us at sales@towardshealthcare.com
Keypoints
- Company Overview
- Locations Subsidiaries/Geographic reach
- Key Executives
- Company Financials
- Patents registered
- SWOT Analysis
- Applications Catered
- Strategic collaborations
- Recent Developments
- Competitive Benchmarking